Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EASTMAN CHEMICAL COEMN · Entity 1780 | Director | October 07, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EASTMAN CHEMICAL CO
Report date October 07, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 61,396 |
Reported balance
After 2026-10-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-07 · Grant · Acquired 1,362 · Balance 61,396 F1: Phantom Stock Units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market of one share of issuer common stock and payable only in cash after termination of service as a director. F2: Voluntary deferral of a portion of director's retainer fees that would otherwise have been paid in cash. F3: Includes dividend equivalents reinvested in additional Phantom Stock Units. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 63,709 |
Reported balance
After 2026-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-07 · Grant · Acquired 480 · Balance 63,709 F1: Phantom Stock Units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market of one share of issuer common stock and payable only in cash after termination of service as a director. F4: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Director's Deferred Compensation Plan. F5: Includes units credited since April 8, 2026, as reinvestment of dividend equivalents for phantom shares deferred under the Directors' Deferred Compensation Plan ("DDCP"), including credits for accrued dividend equivalents that were made to the directors DDCP account on October 7, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Phantom Stock Units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market of one share of issuer common stock and payable only in cash after termination of service as a director.
F2: Voluntary deferral of a portion of director's retainer fees that would otherwise have been paid in cash.
F3: Includes dividend equivalents reinvested in additional Phantom Stock Units.
F4: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Director's Deferred Compensation Plan.
F5: Includes units credited since April 8, 2026, as reinvestment of dividend equivalents for phantom shares deferred under the Directors' Deferred Compensation Plan ("DDCP"), including credits for accrued dividend equivalents that were made to the directors DDCP account on October 7, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MONSANTO CO /NEW/
Report date June 07, 2018 · Filed June 07, 2018
Section 16 reporting ended · disclosed 2018-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2018-06-07 · Disposition to issuer · Disposed 65,405 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2018-06-07 · Disposition to issuer · Disposed 36,899 · Balance 0 F4: Represents restricted stock units. F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2018-06-07 · Disposition to issuer · Disposed 69,772 · Balance 0 F5: Represents performance-based restricted stock units. F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 0 |
Reported balance
After 2018-06-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-06-07 · Disposition to issuer · Disposed 27,769 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 0 |
Reported balance
After 2018-06-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-06-07 · Disposition to issuer · Disposed 7,109 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.45 | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-06-07 · Disposition to issuer · Disposed 31,450 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.48 | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-06-07 · Disposition to issuer · Disposed 41,450 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.05 | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-06-07 · Disposition to issuer · Disposed 42,440 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.82 | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-06-07 · Disposition to issuer · Disposed 39,890 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.34 | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-06-07 · Disposition to issuer · Disposed 82,120 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. |
| Deferred Payment Plan Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-06-07 · Disposition to issuer · Disposed 9,972 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
| Phantom Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-06-07 · Disposition to issuer · Disposed 12,683 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration").
F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
F4: Represents restricted stock units.
F5: Represents performance-based restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2018 Filed Jun 7, 2018 16:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Disposition to issuerCommon Stock | 69,772 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-015475 · doc4.xml · nonDerivative · entry 5 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · shares: Represents performance-based restricted stock units. F1 · price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 16:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Disposition to issuerCommon Stock | 36,899 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-015475 · doc4.xml · nonDerivative · entry 4 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · shares: Represents restricted stock units. F1 · price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 16:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Disposition to issuerCommon Stock | 7,109 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-015475 · doc4.xml · nonDerivative · entry 3 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Plan Disclosed balance after: 0 F1 · price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 16:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Disposition to issuerCommon Stock | 27,769 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-015475 · doc4.xml · nonDerivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 0 F1 · price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 16:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Disposition to issuerCommon Stock | 65,405 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-015475 · doc4.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. Read SEC document |
| May 03, 2018 Filed May 7, 2018 16:04 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantCommon Stock | 827 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-011597 · doc4.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 F1 · shares: Restricted shares, with restrictions generally lapsing immediately prior to election of the issuer's directors at the annual meeting of stockholders on May 2, 2019, subject to certain conditions related to continued service as a director. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 19:11 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantPhantom Stock Units · Derivative | 293 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009850 · doc4.xml · derivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,846 Underlying: Common Stock · 293 shares Expires not disclosed F1 · derivative.exercise_price: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F4 · shares: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F4 · price: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F1 · derivative.exercise_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F1 · derivative.expiration_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F4 · derivative.underlying_shares: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F3 · balance_after: Includes 127 units credited since October 2, 2017 as hypothetical reinvestment of dividend equivalents. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 19:11 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantPhantom Stock Units · Derivative | 588 | $102.85 Strike: $0.00 | $60,475.80 |
DisclosureSEC source: 0000899243-18-009850 · doc4.xml · derivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,553 Underlying: Common Stock · 588 shares Expires not disclosed F1 · derivative.exercise_price: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F2 · shares: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F2 · price: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F1 · derivative.exercise_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F1 · derivative.expiration_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F2 · derivative.underlying_shares: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F3 · balance_after: Includes 127 units credited since October 2, 2017 as hypothetical reinvestment of dividend equivalents. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 16:12 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Tax withholdingCommon Stock | 3,720 | $117.26 | $436,207.20 |
DisclosureSEC source: 0001110783-17-000261 · edgar.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,304 F1 · shares: On November 15, 2017, 8,156 time-based restricted stock units became fully vested for which taxes became due and payable. 3,720 restricted stock units were used for the payment of these taxes. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 16:08 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 20,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000210 · edgar.xml · nonDerivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,609 F2 · shares: Restricted stock unit grant pursuant to the Monsanto Company 2005 Long-Term Incentive Plan, vesting one-third on November 15, 2018, one-third on November 15, 2019 and the remaining one-third on November 15, 2020. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 16:08 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 20,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000210 · edgar.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,024 F1 · shares: Restricted stock unit grant pursuant to the Monsanto Company 2005 Long-Term Incentive Plan, vesting on November 15, 2017. Read SEC document |
| October 26, 2017 Filed Nov 16, 2017 16:10 UTC Amendment | MONSANTO CO /NEW/ MON · Entity 165931 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000260 · edgar.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,024 F1 · balance_after: On October 30, 2017, the Company mistakenly filed a Form 4 on the reporting person's behalf reporting 20,585 restricted stock units vesting on November 15, 2017 as an acquisition of common stock that did not occur. This amended Form 4 is being filed to reflect the deletion of such transaction. The remaining transaction(s) contained in such Form 4 are not amended hereby. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 13:06 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantPhantom Stock Units · Derivative | 331 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-023402 · doc4.xml · derivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,838 Underlying: Common Stock · 331 shares Expires not disclosed F1 · derivative.exercise_price: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F4 · shares: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F4 · price: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F1 · derivative.exercise_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F1 · derivative.expiration_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F4 · derivative.underlying_shares: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F3 · balance_after: Includes 121 units credited since April 3, 2017 as hypothetical reinvestment of dividend equivalents. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 13:06 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantPhantom Stock Units · Derivative | 664 | $90.98 Strike: $0.00 | $60,410.72 |
DisclosureSEC source: 0000899243-17-023402 · doc4.xml · derivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,507 Underlying: Common Stock · 664 shares Expires not disclosed F1 · derivative.exercise_price: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F2 · shares: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F2 · price: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F1 · derivative.exercise_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F1 · derivative.expiration_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F2 · derivative.underlying_shares: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F3 · balance_after: Includes 121 units credited since April 3, 2017 as hypothetical reinvestment of dividend equivalents. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 17:21 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Exercise / conversionOption (Right to Buy) · Derivative | 22,640 | $0.00 Strike: $74.79 | $0.00 |
DisclosureSEC source: 0001110783-17-000166 · edgar.xml · derivative · entry 6 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,640 shares Expires 2021-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-third of the options became exercisable on November 15, 2012, one-third of the options became exercisable on November 15, 2013 and the remainder of the options became exercisable on November 15, 2014, subject to the terms and conditions of the Monsanto Company 2005 Long-Term Incentive Plan. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 17:21 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | SaleCommon Stock | 22,640 | $120.03 | $2,717,576.55 |
DisclosureSEC source: 0001110783-17-000166 · edgar.xml · nonDerivative · entry 3 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,439 F1 · shares: The sale and stock option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 17, 2017. F2 · price: This price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $120.00 to $120.085. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 17:21 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Exercise / conversionCommon Stock | 22,640 | $74.79 | $1,693,245.60 |
DisclosureSEC source: 0001110783-17-000166 · edgar.xml · nonDerivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale and stock option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 17, 2017. Read SEC document |
| July 07, 2017 Filed Sep 27, 2017 17:21 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GiftCommon Stock | 32,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000166 · edgar.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,439 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 16:05 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Exercise / conversionOption (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $74.79 | $0.00 |
DisclosureSEC source: 0001110783-17-000082 · edgar.xml · derivative · entry 7 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,640 Underlying: Common Stock · 25,000 shares Expires 2021-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-third of the options became exercisable on November 15, 2012, one-third of the options became exercisable on November 15, 2013 and the remainder of the options became exercisable on November 15, 2014, subject to the terms and conditions of the Monsanto Company 2005 Long-Term Incentive Plan. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 16:05 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | SaleCommon Stock | 25,000 | $117.51 | $2,937,702.50 |
DisclosureSEC source: 0001110783-17-000082 · edgar.xml · nonDerivative · entry 4 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,712 F1 · shares: The sale and stock option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 17, 2017. F2 · price: This price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $117.50 to $117.5525. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 16:05 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Exercise / conversionCommon Stock | 25,000 | $74.79 | $1,869,750.00 |
DisclosureSEC source: 0001110783-17-000082 · edgar.xml · nonDerivative · entry 3 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale and stock option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 17, 2017. Read SEC document |
| May 22, 2017 Filed Jun 5, 2017 16:05 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GiftCommon Stock | 520 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000082 · edgar.xml · nonDerivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,712 Read SEC document |
| May 19, 2017 Filed Jun 5, 2017 16:05 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GiftCommon Stock | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000082 · edgar.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,232 Read SEC document |
| May 04, 2017 Filed May 8, 2017 21:13 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantCommon Stock | 1,089 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-012253 · doc4.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,193 F1 · shares: Restricted shares, with restrictions generally lapsing immediately prior to election of the issuer's directors at the annual meeting of stockholders on May 3, 2018, subject to certain conditions related to continued service as a director. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 09:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Exercise / conversionOption (Right to Buy) · Derivative | 51,100 | $0.00 Strike: $58.71 | $0.00 |
DisclosureSEC source: 0001110783-17-000052 · edgar.xml · derivative · entry 7 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,100 shares Expires 2020-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-third of the options became exercisable on November 15, 2011, one-third of the options became exercisable on November 15, 2012 and the remainder of the options became exercisable on November 15, 2013, subject to the terms and conditions of the Monsanto Company 2005 Long Term Incentive Plan. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 09:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Exercise / conversionOption (Right to Buy) · Derivative | 29,840 | $0.00 Strike: $70.69 | $0.00 |
DisclosureSEC source: 0001110783-17-000052 · edgar.xml · derivative · entry 6 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,840 shares Expires 2019-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-third of the options became exercisable on November 15, 2010, one-third of the options became exercisable on November 15, 2011 and the remainder of the options became exercisable on November 15, 2012, subject to the terms and conditions of the Monsanto Company 2005 Long-Term Incentive Plan. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 09:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | SaleCommon Stock | 80,940 | $116.13 | $9,399,691.70 |
DisclosureSEC source: 0001110783-17-000052 · edgar.xml · nonDerivative · entry 3 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,407 F1 · shares: The sale and stock option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 17, 2017. F2 · price: This price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $115.75 to $116.275. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 09:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Exercise / conversionCommon Stock | 51,100 | $58.71 | $3,000,081.00 |
DisclosureSEC source: 0001110783-17-000052 · edgar.xml · nonDerivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale and stock option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 17, 2017. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 09:54 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Exercise / conversionCommon Stock | 29,840 | $70.69 | $2,109,389.60 |
DisclosureSEC source: 0001110783-17-000052 · edgar.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale and stock option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 17, 2017. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 13:10 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantPhantom Stock Units · Derivative | 377 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-009421 · doc4.xml · derivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,722 Underlying: Common Stock · 377 shares Expires not disclosed F1 · derivative.exercise_price: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F4 · shares: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F4 · price: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F1 · derivative.exercise_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F1 · derivative.expiration_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F4 · derivative.underlying_shares: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F3 · balance_after: Includes 143 units credited since October 3, 2016 as hypothetical reinvestment of dividend equivalents. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 13:10 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantPhantom Stock Units · Derivative | 756 | $79.96 Strike: $0.00 | $60,449.76 |
DisclosureSEC source: 0000899243-17-009421 · doc4.xml · derivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,345 Underlying: Common Stock · 756 shares Expires not disclosed F1 · derivative.exercise_price: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F2 · shares: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F2 · price: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F1 · derivative.exercise_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F1 · derivative.expiration_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F2 · derivative.underlying_shares: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F3 · balance_after: Includes 143 units credited since October 3, 2016 as hypothetical reinvestment of dividend equivalents. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:17 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Tax withholdingCommon Stock | 4,059 | $99.09 | $402,206.31 |
DisclosureSEC source: 0001110783-16-000593 · edgar.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,407 F1 · shares: On November 15, 2016, 9,506 performance-based restricted stock units became fully vested for which taxes became due and payable. 4,059 restricted stock units were used for the payment of these taxes. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 17:21 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 24,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-16-000537 · edgar.xml · nonDerivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,466 F2 · shares: Restricted stock unit grant pursuant to the Monsanto Company 2005 Long-Term Incentive Plan, vesting one-third on November 15, 2017, one-third on November 15, 2018 and the remaining one-third on November 15, 2019. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 17:21 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 9,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-16-000537 · edgar.xml · nonDerivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,996 F1 · shares: Restricted stock unit grant pursuant to the Monsanto Company 2005 Long-Term Incentive Plan, vesting on November 15, 2016. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 22:34 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantPhantom Stock Units · Derivative | 448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-030970 · doc4.xml · derivative · entry 2 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,446 Underlying: Common Stock · 448 shares Expires not disclosed F1 · derivative.exercise_price: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F4 · shares: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F4 · price: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F1 · derivative.exercise_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F1 · derivative.expiration_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F4 · derivative.underlying_shares: Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan. F3 · balance_after: Includes 182 units credited since April 1, 2016 as hypothetical reinvestment of dividend equivalents. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 22:34 UTC | EASTMAN CHEMICAL CO EMN · Entity 1780 | GrantPhantom Stock Units · Derivative | 838 | $67.19 Strike: $0.00 | $56,305.22 |
DisclosureSEC source: 0000899243-16-030970 · doc4.xml · derivative · entry 1 BEGEMANN BRETT D · CIK 0001243982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,998 Underlying: Common Stock · 838 shares Expires not disclosed F1 · derivative.exercise_price: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F2 · shares: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F2 · price: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F1 · derivative.exercise_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F1 · derivative.expiration_date: Phantom Stock units credited under the Directors' Deferred Compensation Plan, each having a value equal to the market value of one share of issuer common stock and payable only in cash after termination of service as a director. F2 · derivative.underlying_shares: Voluntary deferral at election of director of a portion of director's retainer fees that would otherwise have been paid in cash into the director's stock account of the Directors' Deferred Compensation Plan. F3 · balance_after: Includes 182 units credited since April 1, 2016 as hypothetical reinvestment of dividend equivalents. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.